Growth hormone treatment in Léri-Weill syndrome

J Pediatr Endocrinol Metab. 1996 Mar-Apr;9(2):201-4.

Abstract

Five children with dyschondrosteosis (Léri-Weill syndrome) were found to have insufficient growth hormone (GH) secretion and were treated with GH. After one year of treatment height velocity SDS as well as height SDS increased significantly. In three children who had completed their second year of treatment, the increase in height velocity was sustained and for all patients predicted adult height increased during the GH treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Arginine
  • Body Height
  • Body Weight
  • Child
  • Female
  • Human Growth Hormone / metabolism
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Insulin
  • Male
  • Osteochondrodysplasias / drug therapy*
  • Osteochondrodysplasias / physiopathology
  • Syndrome

Substances

  • Insulin
  • Human Growth Hormone
  • Arginine